**Supplementary Table 5. Relationship between circRNA and patients’ laboratory features**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Variables | | circRNA value | | Independent sample t-test | *p*-value |
| **Mean** | **+ SD** |
| Platelets (×10³/µL) categories | **Normal (>=150)** | 5.41 | 2.05 | 0.038 | 0.846 |
| **Thrombocytopenia (<150)** | 5.60 | 2.80 |
| AFP (ng/mL) categories | **Normal (0-19)** | 5.52 | 2.49 |  |  |
| **Mildly elevated (20-100)** | . | . |
| **Moderately Elevated (101-200)** | . | . |
| **Severely elevated (201-1000)** | . | . |
| **Extremely elevated (>1000)** | . | . |
| ALBI categories | **Grade I (<=-2.60)** | . | . | 0.626 | 0.436 |
| **Grade 2 (>-2.60-<=-1.39)** | 5.29 | 2.17 |
| **Grade 3 (>-1.39)** | 6.08 | 3.19 |
| CRP (mg/L) categories | **Normal (<=6)** | 5.85 | 2.54 | 2.207 | 0.149 |
| **Elevated (>6)** | 4.20 | 1.89 |
| NLR categories | **Normal (1-5)** | 3.73 | .78 | 9.103# | 0.001\*\* |
| **Mild (6-8)** | 8.21 | .00 |
| **Moderate (9-18)** | 6.42 | 2.68 |
| **Severe (>18)** | . | . |
| PLR categories | **Low levels (<106)** | 3.30 | .91 | 8.525# | 0.001\*\* |
| **Normal levels (106-300)** | 5.18 | 2.58 |
| **High levels (>300)** | 7.58 | 1.26 |
| AST/ALT ratio categories | **Low (<=1)** | 5.32 | .66 | 0.048 | 0.827 |
| **High (>1)** | 5.57 | 2.78 |
| FIB 4 categories | **Stage 0-1 (<1.45)** | 5.32 | .66 | 2.348# | 0.115 |
| **Stage 2-3 (1.45-3.25)** | 2.80 | .00 |
| **Stage 4-6 (stage 4-6)** | 5.97 | 2.75 |
| APRI categories | **No significant fibrosis (<0.07)** | 4.48 | 1.36 | 1.167# | 0.326 |
| **Significant fibrosis (0.7-1)** | 6.17 | 2.23 |
| **Severe fibrosis/Cirrhosis (>1)** | 5.89 | 3.00 |
| NFS categories | **F0-F2 (<-1.455)** | 4.36 | 1.71 | 1.159# | 0.329 |
| **Indeter. score (-1.455-0.675)** | 4.71 | .00 |
| **F3-F4 (>0.675)** | 5.97 | 2.75 |
| CTP score | **A** | 3.59 | .86 | 65.338# | 0.000\*\* |
| **Early B** | . | . |
| **Late B** | 4.45 | 1.37 |
| **C** | 8.88 | .73 |
| MELD categories | **Low risk (<10)** | . | . | 5.833 | 0.023\* |
| **Moderate risk (10-19)** | 5.86 | 2.39 |
| **High risk (20-30)** | 2.47 | .00 |
| **Very high (>30)** | . | . |

#A one-way ANOVA test was used to compare more than two independent group means. \*Statistically significant at *p* < 0.05.\*\*Highly statistically significant at *p* < 0.01. AFP, alpha-feto protein; ALBI, albumin-bilirubin score; ALT, alanine aminotransferase; ANOVA, analysis of variance; APRI, AST to Platelet Ratio Index; AST, aspartate aminotransferase; circRNA, circular RNA; CRP, C. reactive protein; CTP, Child-Turcotte-Pugh; FIB-4, Fibrosis-4 ; MELD, Model for End-Stage Liver Disease score; NFS, Nonalcoholic Fatty Liver Disease Fibrosis Score; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; SD, standard deviation.